AVROBIO Inc. (AVRO)’s Financial Results Comparing With Athersys Inc. (NASDAQ:ATHX)

AVROBIO Inc. (NASDAQ:AVRO) and Athersys Inc. (NASDAQ:ATHX), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AVROBIO Inc. N/A 0.00 40.22M -1.74 0.00
Athersys Inc. 23.95M 8.88 26.06M -0.21 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of AVROBIO Inc. and Athersys Inc.


Table 2 represents AVROBIO Inc. (NASDAQ:AVRO) and Athersys Inc. (NASDAQ:ATHX)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
AVROBIO Inc. 0.00% 0% 0%
Athersys Inc. -108.81% -58.7% -44.6%


The Current Ratio and Quick Ratio of AVROBIO Inc. are 25.8 and 25.8 respectively. Its competitor Athersys Inc.’s Current Ratio is 4.6 and its Quick Ratio is 4.6. AVROBIO Inc. can pay off short and long-term obligations better than Athersys Inc.

Insider & Institutional Ownership

The shares of both AVROBIO Inc. and Athersys Inc. are owned by institutional investors at 70.3% and 23.7% respectively. Insiders held 0.1% of AVROBIO Inc. shares. On the other hand, insiders held about 2.1% of Athersys Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AVROBIO Inc. -5.95% 28.17% -34.23% -55.14% 0% -4.08%
Athersys Inc. 1.97% -2.52% -19.69% -22.89% 15.67% 7.64%

For the past year AVROBIO Inc. had bearish trend while Athersys Inc. had bullish trend.


Athersys Inc. beats on 5 of the 9 factors AVROBIO Inc.

AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease. The company is also developing AVR-RD-02 for the treatment of type 1 gaucher disease; AVR-RD-03 for the treatment of pompe disease; and AVR-RD-04 for the treatment of cystinosis. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.